Sinco Pharma Chairman Huang Xiangbin Resigns; Board Temporarily Breaches HKEX Nomination-Committee Rule

Bulletin Express04-30

Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) announced that Mr. Huang Xiangbin has resigned, with immediate effect from 30 April 2026, as Chairman of the Board, Executive Director, Chairman of the Nomination Committee and Authorised Representative under HKEX Listing Rule 3.05. The departure is attributed to his desire to devote more time to other commitments. Mr. Huang has confirmed there is no disagreement with the Board and no other matters requiring shareholder or regulator attention.

Mr. Huang Zhijian, currently Vice Chairman and Executive Director, has been appointed as the company’s new Authorised Representative effective the same day, ensuring continuity in external communications with the Hong Kong Stock Exchange.

Following the resignation, the position of Chairman of the Nomination Committee remains vacant, placing Sinco Pharma in temporary non-compliance with Listing Rule 3.27A, which mandates that the committee be chaired by the Board Chairman or an independent non-executive director. In line with Rule 3.27C, the Board intends to fill the vacancy within three months and will issue further announcements as appropriate.

As of 30 April 2026, the Board comprises two Executive Directors (Mr. Huang Zhijian and Mr. Lei Shifeng), one Non-executive Director (Ms. Jing Huan) and four Independent Non-executive Directors (Mr. Bai Zhizhong, Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162372914?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162372914","market":"hk","top_or_hot":-1,"title":"Sinco Pharma Chairman Huang Xiangbin Resigns; Board Temporarily Breaches HKEX Nomination-Committee Rule","media":"Bulletin Express","content":"<p>Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) announced that Mr. Huang Xiangbin has resigned, with immediate effect from 30 April 2026, as Chairman of the Board, Executive Director, Chairman of the Nomination Committee and Authorised Representative under HKEX Listing Rule 3.05. The departure is attributed to his desire to devote more time to other commitments. Mr. Huang has confirmed there is no disagreement with the Board and no other matters requiring shareholder or regulator attention.</p>\n<p>Mr. Huang Zhijian, currently Vice Chairman and Executive Director, has been appointed as the company’s new Authorised Representative effective the same day, ensuring continuity in external communications with the Hong Kong Stock Exchange.</p>\n<p>Following the resignation, the position of Chairman of the Nomination Committee remains vacant, placing Sinco Pharma in temporary non-compliance with Listing Rule 3.27A, which mandates that the committee be chaired by the Board Chairman or an independent non-executive director. In line with Rule 3.27C, the Board intends to fill the vacancy within three months and will issue further announcements as appropriate.</p>\n<p>As of 30 April 2026, the Board comprises two Executive Directors (Mr. Huang Zhijian and Mr. Lei Shifeng), one Non-executive Director (Ms. Jing Huan) and four Independent Non-executive Directors (Mr. Bai Zhizhong, Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinco Pharma Chairman Huang Xiangbin Resigns; Board Temporarily Breaches HKEX Nomination-Committee Rule</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinco Pharma Chairman Huang Xiangbin Resigns; Board Temporarily Breaches HKEX Nomination-Committee Rule\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-30 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) announced that Mr. Huang Xiangbin has resigned, with immediate effect from 30 April 2026, as Chairman of the Board, Executive Director, Chairman of the Nomination Committee and Authorised Representative under HKEX Listing Rule 3.05. The departure is attributed to his desire to devote more time to other commitments. Mr. Huang has confirmed there is no disagreement with the Board and no other matters requiring shareholder or regulator attention.</p>\n<p>Mr. Huang Zhijian, currently Vice Chairman and Executive Director, has been appointed as the company’s new Authorised Representative effective the same day, ensuring continuity in external communications with the Hong Kong Stock Exchange.</p>\n<p>Following the resignation, the position of Chairman of the Nomination Committee remains vacant, placing Sinco Pharma in temporary non-compliance with Listing Rule 3.27A, which mandates that the committee be chaired by the Board Chairman or an independent non-executive director. In line with Rule 3.27C, the Board intends to fill the vacancy within three months and will issue further announcements as appropriate.</p>\n<p>As of 30 April 2026, the Board comprises two Executive Directors (Mr. Huang Zhijian and Mr. Lei Shifeng), one Non-executive Director (Ms. Jing Huan) and four Independent Non-executive Directors (Mr. Bai Zhizhong, Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06833","symbol_name":"兴科蓉医药","start_time":0,"source_url":"","article_id":"1162372914","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162372914","pubTimestamp":1777550588,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) announced that Mr. Huang Xiangbin has resigned, with immediate effect from 30 April 2026, as Chairman of the Board, Executive Director, Chairman...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06833":"兴科蓉医药"},"translate_title":"新科制药董事长黄祥斌辞职；董事会暂时违反香港交易所提名委员会规则","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06833":1},"content_text":"Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) announced that Mr. Huang Xiangbin has resigned, with immediate effect from 30 April 2026, as Chairman of the Board, Executive Director, Chairman of the Nomination Committee and Authorised Representative under HKEX Listing Rule 3.05. The departure is attributed to his desire to devote more time to other commitments. Mr. Huang has confirmed there is no disagreement with the Board and no other matters requiring shareholder or regulator attention.\nMr. Huang Zhijian, currently Vice Chairman and Executive Director, has been appointed as the company’s new Authorised Representative effective the same day, ensuring continuity in external communications with the Hong Kong Stock Exchange.\nFollowing the resignation, the position of Chairman of the Nomination Committee remains vacant, placing Sinco Pharma in temporary non-compliance with Listing Rule 3.27A, which mandates that the committee be chaired by the Board Chairman or an independent non-executive director. In line with Rule 3.27C, the Board intends to fill the vacancy within three months and will issue further announcements as appropriate.\nAs of 30 April 2026, the Board comprises two Executive Directors (Mr. Huang Zhijian and Mr. Lei Shifeng), one Non-executive Director (Ms. Jing Huan) and four Independent Non-executive Directors (Mr. Bai Zhizhong, Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162372914","isCrawlerRequest":true}